Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
复制标题
DOI：
10.1016/j.ebiom.2021.103626
复制
发表时间：
2021-11
期刊：
影响因子：
11.1
通讯作者：
Simon V
中科院分区：
文献类型：
--
作者：
Carreño JM;Alshammary H;Singh G;Raskin A;Amanat F;Amoako A;Gonzalez-Reiche AS;van de Guchte A;Study Group P;Srivastava K;Sordillo EM;Sather DN;van Bakel H;Krammer F;Simon V
针对严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的高效疫苗已经开发出来。然而，比早期SARS-CoV-2毒株更具传染性的病毒变体的出现令人担忧。其中一些病毒变体有可能部分逃避中和抗体反应，因此需要继续进行免疫监测。我们使用了一组30个mrna后疫苗接种血清来确定中和和RBD以及对许多新出现的病毒变体的刺突结合活性。使用真实的SARS-CoV-2临床分离株，以模拟生理条件的检测格式确定病毒中和作用。我们在中和试验中测试了目前流行的七种病毒变体，包括三种Iota亚谱系，Alpha (E484K), Beta， Delta和Lambda。我们发现对Iota和Delta的中和作用只有很小的下降。对Lambda的子变体的还原更强，其次是Beta和Alpha （E484K）。Lambda目前在拉丁美洲部分地区传播，并在德国、美国和以色列被发现。值得注意的是，包括Gamma、Kappa和a .23.1在内的受体结合域和刺突结合试验的减少可以忽略不计。综上所述，这些发现表明mRNA SARS-CoV-2疫苗可能对这些关注/感兴趣的病毒变体仍然有效，并且面对不断变化的SARS-CoV-2多样性，刺突结合抗体测试可能保持特异性。这项工作是NIAID合作流感疫苗创新中心（CIVIC）合同75N93019C00051资助的PARIS/SPARTA研究的一部分。此外，这项工作还部分由流感研究和监测卓越中心（CEIRS，合同# HHSN272201400008C）、JPB基金会、开放慈善项目（研究资助2020-215611(5384)）、匿名捐赠者和血清学科学网络（SeroNet）资助，部分由美国国立卫生研究院国家癌症研究所联邦基金资助，合同编号为75N91019D00024，任务订单号为75N91020F00003。
Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning. Several of these viral variants have the potential to partially escape neutralizing antibody responses, warranting continued immune-monitoring. We used a panel of 30 post-mRNA vaccination sera to determine neutralization and RBD and spike binding activity against a number of emerging viral variants. The virus neutralization was determined using authentic SARS-CoV-2 clinical isolates in an assay format that mimics physiological conditions. We tested seven currently circulating viral variants of concern/interest, including the three Iota sublineages, Alpha (E484K), Beta, Delta and Lambda in neutralization assays. We found only small decreases in neutralization against Iota and Delta. The reduction was stronger against a sub-variant of Lambda, followed by Beta and Alpha (E484K). Lambda is currently circulating in parts of Latin America and was detected in Germany, the US and Israel. Of note, reduction in a receptor binding domain and spike binding assay that also included Gamma, Kappa and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity. This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384), by anonymous donors and by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003.
登录
查看更多内容
影响因子：
16.6
作者：
Li B;Deng A;Li K;Hu Y;Li Z;Shi Y;Xiong Q;Liu Z;Guo Q;Zou L;Zhang H;Zhang M;Ouyang F;Su J;Su W;Xu J;Lin H;Sun J;Peng J;Jiang H;Zhou P;Hu T;Luo M;Zhang Y;Zheng H;Xiao J;Liu T;Tan M;Che R;Zeng H;Zheng Z;Huang Y;Yu J;Yi L;Wu J;Chen J;Zhong H;Deng X;Kang M;Pybus OG;Hall M;Lythgoe KA;Li Y;Yuan J;He J;Lu J
通讯作者：
Lu J
影响因子：
56.9
作者：
Gonzalez-Reiche, Ana S.;Hernandez, Matthew M.;van Bakel, Harm
通讯作者：
van Bakel, Harm
中和和非中和人类H7N9流感疫苗诱导的单克隆抗体提供保护。
影响因子：
30.3
作者：
Henry Dunand CJ;Leon PE;Huang M;Choi A;Chromikova V;Ho IY;Tan GS;Cruz J;Hirsh A;Zheng NY;Mullarkey CE;Ennis FA;Terajima M;Treanor JJ;Topham DJ;Subbarao K;Palese P;Krammer F;Wilson PC
通讯作者：
Wilson PC
影响因子：
15.9
作者：
Levi, Riccardo;Azzolini, Elena;Rescigno, Maria
通讯作者：
Rescigno, Maria
影响因子：
28.3
作者：
Bugembe DL;Phan MVT;Ssewanyana I;Semanda P;Nansumba H;Dhaala B;Nabadda S;O'Toole ÁN;Rambaut A;Kaleebu P;Cotten M
通讯作者：
Cotten M